PRESS STATEMENT: New Kaiser Family Foundation Poll Reinforces Need for Sustainable Drug Pricing

06-16-2015 Blog PostsPress Release

John Rother, President of the National Coalition on Health Care and Chair of the Campaign for Sustainable Rx Pricing issued the following statement in response to a recent health tracking poll by the Kaiser Family Foundation that found that an overwhelming 76% of Americans blame pharmaceutical companies for the rising cost of medicines.

ICYMI: New poll shows 75% of Americans find Rx prices are just too high.

05-21-2015 Blog PostsPress Release

May 21, 2015 Morning Consult: “New Cures, Old Problems: Poll Shows Drug Affordability Addles Americans” “The House Energy and Commerce Committee is slated to vote today on legislation that offers incentives to the pharmaceutical industry to develop new drugs and devices. But the bill does little immediately to address what a new Morning Consult poll found […]

ICYMI: “Prescription drug prices climb into the stratosphere”

05-20-2015 Blog PostsPress Release

May 20, 2015 “Prescription drug prices climb into the stratosphere” by Trudy Lieberman, Rural Health News Service Note: Article originally printed in Sterling Journal-Advocate.  There’s no getting around it. Americans are using more medications and spending more for them. The latest evidence just came from Express Scripts, the pharmacy benefit manager, which acts as a middleman […]

ICYMI: New study answers the age old question, “Does R&D really justify high drug costs?” (Spoiler alert: the answer is no.)

05-15-2015 Blog PostsPress Release

ICYMI – May 15, 2015 ***** The New England Journal of Medicine: “The $2.6 Billion Pill — Methodologic and Policy Considerations” “Of course, it is extremely expensive and risky to develop a new medication…but as risky as drug development is, the pharmaceutical and biotech industries remain among the most profitable sectors of the U.S. economy and actually […]

ICYMI: In anticipation of today’s Cures markup, E&C releases an updated draft while Pew launches a new Rx initiative

05-14-2015 Blog PostsPress Release

May 14, 2015 The House Energy and Commerce Committee released an updated draft of the 21st Century Cures bill last night in a last minute effort to address concerns over drug exclusivity, interoperability and tele health before today’s markup. However, many organizations are still concerned about Congress’ lack of legislation to address high drug costs. Pew Charitable Trusts […]

ICYMI: FDA Advisory Panel Approves New Cystic-Fibrosis Drug while Americans Continue to Pay the Price of High Cost Drugs

05-13-2015 Blog PostsPress Release

May 13, 2015 The New York Times: “Cystic Fibrosis Drug Wins Approval of F.D.A. Advisory Panel” “If the drug is approved, Vertex could still face challenges getting insurers to pay for it, given the somewhat questionable efficacy. Kalydeco costs more than $300,000 a year, although Orkambi is expected to be a little less expensive, because it […]

ICYMI: “As E&C Prepares Cures Bill Markup, Negative Press On Drug Prices On The Increase”

05-12-2015 Blog PostsPress Release

May 12, 2015 Health Reform Insider: “As E&C Prepares Cures Bill Markup, Negative Press On Drug Prices On The Increase”  Note: subscription required to view full article on “The House Energy & Commerce Committee will begin marking up 21st Century Cures legislation Thursday (April 14), but those paying for drugs worry that speeding drug and […]

ICYMI: Vertex’s Cystic-Fibrosis Drug Could Come at a Cost

05-11-2015 Blog PostsPress Release

May 11, 2015 The Wall Street Journal: “Vertex’s Cystic-Fibrosis Drug Faces Big Test” The FDA meeting, to be held in Gaithersburg, Md., will be closely watched by health insurers and pharmacy-benefit managers who are concerned that Orkambi will be the latest high-priced blockbuster to strain their budgets. Vertex hasn’t announced a price yet, but J.P. Morgan […]

Weekly Update – How much is too much?

05-8-2015 Blog PostsNewsletterPress Release

Weekly Update – 5/8/2015 We learned this week that worldwide spending on cancer medicines reached $100 billion in 2014, an increase of 10.3 percent from 2013. And let’s not forget about last week’s multiple sclerosis study noting that there has been an “alarming rise” in the cost of these drugs, coming in between $50,000 and […]

ICYMI: Should the Specialty Drug Cost Debate Take a Breath? Data Proves Otherwise.

05-7-2015 Blog PostsPress Release

ICYMI: May 7, 2015 “Take a Breath” on the Specialty Drug Pricing Issue…? “…for anyone who thinks the players involved in this specialty drug pricing confrontation will actually “take a breath” and voluntarily work towards better access and lower prices, I am sorry. You’re not being realistic. Here’s the truth: As long as we have […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.